Development of anti-TNF therapy for rheumatoid arthritis

[1]  H. Hengartner,et al.  Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis , 2004, Rheumatology International.

[2]  D. Isenberg,et al.  Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. , 2002, Rheumatology.

[3]  R. Day.  Adverse reactions to TNF-α inhibitors in rheumatoid arthritis , 2002, The Lancet.

[4]  M. Feldmann,et al.  Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[5]  A. Webster,et al.  Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. , 2005, The Cochrane database of systematic reviews.

[6]  D. Pisetsky,et al.  Progress in the treatment of rheumatoid arthritis. , 2001, JAMA.

[7]  Joseph Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent , 2001 .

[8]  M. Feldmann,et al.  Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. , 2001, Arthritis and rheumatism.

[9]  G. Morstyn,et al.  Filgrastim (r-metHuG-CSF) in the 21st Century: SD/01 , 2001, Acta Haematologica.

[10]  U. Chaudhari,et al.  Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial , 2001, The Lancet.

[11]  M. Feldmann,et al.  Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? , 2001, Annual review of immunology.

[12]  J. Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.

[13]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[14]  U. Andersson,et al.  Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. , 2000, Arthritis and rheumatism.

[15]  P. Mease,et al.  Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial , 2000, The Lancet.

[16]  J. Braun,et al.  Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. , 2000, Arthritis and rheumatism.

[17]  Richard W. Martin,et al.  A PHASE III TRIAL OF ETANERCEPT vs METHOTREXATE (MTX) IN EARLY RHEUMATOID ARTHRITIS (ENBREL ERA TRIAL) , 2000 .

[18]  A. Reiff,et al.  Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. , 2000, The New England journal of medicine.

[19]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[20]  C. Edwards.  PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases , 1999, Annals of the rheumatic diseases.

[21]  J. Kempeni.  Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7 , 1999, Annals of the rheumatic diseases.

[22]  B. Bozkurt,et al.  Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. , 1999, Circulation.

[23]  P. Rutgeerts,et al.  Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.

[24]  F. Breedveld,et al.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[25]  L. Genestier,et al.  Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. , 1998, The Journal of clinical investigation.

[26]  M. Feldmann,et al.  Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. , 1997, British journal of rheumatology.

[27]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[28]  J. Woody,et al.  Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. , 1997, Advances in immunology.

[29]  L. Moreland,et al.  Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. , 1996, The Journal of rheumatology.

[30]  J. Woody,et al.  Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. , 1996, Arthritis and rheumatism.

[31]  M. Feldmann,et al.  Role of cytokines in rheumatoid arthritis. , 1996, Annual review of immunology.

[32]  R. Maini,et al.  The Role of Cytokines in Rheumatoid Arthritis , 1996, Journal of the Royal College of Physicians of London.

[33]  M. Feldmann,et al.  Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. , 1995, European cytokine network.

[34]  D. Hommes,et al.  Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). , 1995, Gastroenterology.

[35]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[36]  J. Woody,et al.  Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis , 1994, The Lancet.

[37]  J. Dayer,et al.  Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. , 1994, The Journal of biological chemistry.

[38]  A. Cope,et al.  Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. , 1994, The Journal of clinical investigation.

[39]  G. Haines,et al.  Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. , 1994, Journal of immunology.

[40]  M. Feldmann,et al.  Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Ghrayeb,et al.  Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. , 1993, Arthritis and rheumatism.

[42]  B. Scallon,et al.  Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. , 1993, Molecular immunology.

[43]  J. Dayer,et al.  Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69. , 1993, European cytokine network.

[44]  R. Gentz,et al.  Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. , 1992, Immunology.

[45]  M. Feldmann,et al.  Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Palladino,et al.  Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[47]  B. Beutler,et al.  Constitutive activity of the tumor necrosis factor promoter is canceled by the 3' untranslated region in nonmacrophage cell lines; a trans-dominant factor overcomes this suppressive effect. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[48]  D. Kioussis,et al.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.

[49]  B. Beutler,et al.  A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity , 1991, The Journal of experimental medicine.

[50]  M. Feldmann,et al.  Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. , 1991, Arthritis and rheumatism.

[51]  M. Turner,et al.  Expression of granulocyte‐macrophage colony‐stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor‐α , 1991, European journal of immunology.

[52]  G. Firestein,et al.  Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha. , 1991, Journal of immunology.

[53]  W. Coley.  The Classic: The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas , 1991 .

[54]  R. Holmdahl,et al.  Type II Collagen Autoimmunity in Animals and Provocations Leading to Arthritis , 1990, Immunological reviews.

[55]  M. Feldmann,et al.  Cytokine production in the rheumatoid joint: implications for treatment. , 1990, Annals of the rheumatic diseases.

[56]  F. Epstein,et al.  Rheumatoid arthritis. Pathophysiology and implications for therapy. , 1990, The New England journal of medicine.

[57]  H. Paulus,et al.  Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. , 1990, Arthritis and rheumatism.

[58]  M. Feldmann,et al.  INHIBITORY EFFECT OF TNFα ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS , 1989, The Lancet.

[59]  M. Feldmann,et al.  Cytokine production in culture by cells isolated from the synovial membrane. , 1989, Journal of autoimmunity.

[60]  H. Mitsuya,et al.  Designing CD4 immunoadhesins for AIDS therapy , 1989, Nature.

[61]  H. Waldmann,et al.  Manipulation of T-cell responses with monoclonal antibodies. , 1989, Annual review of immunology.

[62]  M. Turner,et al.  Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. , 1988, Clinical and experimental immunology.

[63]  D. Heinegård,et al.  Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. , 1988, Arthritis and rheumatism.

[64]  S. Malawista,et al.  Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1. , 1987, Journal of immunology.

[65]  J. Saklatvala,et al.  Pig interleukin 1. Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever , 1985, The Journal of experimental medicine.

[66]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[67]  D. Goeddel,et al.  Human tumor necrosis factor. Production, purification, and characterization. , 1985, The Journal of biological chemistry.

[68]  Bharat B. Aggarwal,et al.  Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin , 1984, Nature.

[69]  B. Aggarwal,et al.  Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity , 1984, Nature.

[70]  D. Goeddel,et al.  Expression of human immune interferon cDNA in E. coli and monkey cells , 1982, Nature.

[71]  T. Taniguchi,et al.  The nucleotide sequence of human fibroblast interferon cDNA. , 1980, Gene.

[72]  K. Cantell,et al.  Synthesis in E. coli of a polypeptide with human leukocyte interferon activity , 1980, Nature.

[73]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[74]  G. Habicht,et al.  Cellular sites of immunologic unresponsiveness. , 1970, Proceedings of the National Academy of Sciences of the United States of America.

[75]  N. Mitchison,et al.  The mechanism of immunological paralysis. , 1968, Advances in immunology.

[76]  J. Oudin,et al.  [A new allotype form of rabbit serum gamma-globulins, apparently associated with antibody function and specificity]. , 1963, Comptes rendus hebdomadaires des seances de l'Academie des sciences.

[77]  William B. Colev.  I. The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas , 1893 .